Researchers at National Jewish Health have discovered a novel
target for the treatment of food allergies. Erwin Gelfand, MD, and his
colleagues report in the October 2012 issue of the Journal of Allergy
and Clinical Immunology that levels of the enzyme Pim 1 kinase rise in
the small intestines of peanut-allergic mice. Inhibiting activity of Pim 1
markedly reduced the allergic response to peanuts.
"Pim 1, and its associated transcription factor, Runx3, play
a crucial role in allergic reactions to peanuts," said Dr. Gelfand, senior
author and chair of pediatrics at National Jewish Health. "As such, they
offer promising new targets for the treatment of allergic reactions to peanuts,
and possibly other foods."
Pim1 kinase is involved in many signaling pathways and is
expressed in T cells and eosinophils, cell types linked to allergic diseases.
Runx3 is a transcription factor associated with the regulation of T cells.
In a mouse model of food allergy, the researchers found that Pim1
kinase levels increased in the intestines of allergic mice that had been fed
peanuts, as did various inflammatory cells and levels of cytokine molecules
associated with allergies. Levels of Runx3 mRNA, however, dropped significantly
in the allergic mice. When researchers administered a small molecule that
inhibits the activity of Pim 1 kinase, mice no longer experienced diarrhea and
other symptoms associated with their peanut allergy.
Plasma levels of histamine, a potent cause of allergy symptoms,
dropped to almost baseline levels after administration of AR460770, which is
produced by Array Biopharma. Inflammatory mast cells, eosinophils, and CD4 and
CD8 T cells all increased only slightly in response to peanuts. Levels of
several cytokine signaling molecules associated with allergies, IL-4, IL-6 and
IL-13, also dropped after treatment with the Pim 1 inhibitor. Runx3 mRNA, rose
back to near baseline levels.
"Our data identified for the first time that Pim1 kinase
contributes in important ways to the development of peanut-induced allergic
responses, " said Dr. Gelfand. "Targeting this novel regulatory axis
involving Pim 1 kinase and Runx3 offers new therapeutic opportunities for the
control of food-induced allergic reactions."
0 comments:
Post a Comment